Agenus
AGEN
Performance
About Agenus
Agenus is a biotechnology company focused on immuno-oncology, developing antibody-based therapies and combination approaches to expand the patient population benefiting from cancer immunotherapy. The company advances programs in oncology through its own pipelines and through partnerships, with manufacturing and clinical capabilities described across its US and European operations. Its portfolio includes next-generation CTLA-4 antibodies and other immuno-oncology therapeutics, plus subsidiaries involved in adoptive cell therapies and adjuvants/vaccines. Agenus emphasizes curb-to-curate development of curative therapies and access to investigational medicines for patients worldwide.
Recent News
We Are the Largest Oncology Player in India, Says Zydus MD; Eyes US Speciality Push
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
Zydus to Acquire US Cancer Drug Company Assertio for $166.4 Million in All-Cash Deal
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
Agenus Announces Data From Phase II Study of BOT+BAL in Combination with Agent-797 in PD-1 Refractory Gastroesophageal Cancer to Be Presented at AACR 2026
Agenus Closes Strategic Immunotherapeutic Collaboration with Zydus Lifesciences
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus Cancer Cocktail Records 0% Response Rate, Missing Midstage Goal
Biopharma Money Raised: Jan. 1-April 23, 2026
Traws Pharma Announces New Antiviral Program
Open Source Therapeutics Divulges New PARP-1 Inhibitors
Recent Deals
No recent deals for this company.